AcelRx Pharmaceuticals, Inc.

AcelRx Pharmaceuticals, Inc. is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. The momentum for this stock is not very good. AcelRx Pharmaceuticals, Inc. is not a good value stock. AcelRx Pharmaceuticals, Inc. is not a good growth stock. AcelRx Pharmaceuticals, Inc. is not very popular among insiders. AcelRx Pharmaceuticals, Inc. is a mediocre stock to choose.
Log in to see more information.
AcelRx Pharmaceuticals, Inc. engages in the development and commercialization of therapies use in me...
ACRX Fundamental Data by TradingView

News

AcelRx Pharmaceuticals GAAP EPS of -$0.08 beats by $0.20, revenue of $0.12M misses by $0.01M
AcelRx Pharmaceuticals GAAP EPS of -$0.08 beats by $0.20, revenue of $0.12M misses by $0.01M

SeekingAlpha.com: All News AcelRx Pharmaceuticals exceeds expectations with Q3 earnings, beating EPS estimates by $0.20, but falls short on revenue by $0.01M.\n more…

AcelRx Reports Third Quarter 2023 Financial Results and Provides Corporate Update
AcelRx Reports Third Quarter 2023 Financial Results and Provides Corporate Update

PR Newswire AcelRx Reports Third Quarter 2023 Financial Results and Provides Corporate Update AcelRx Reports Third Quarter 2023 Financial Results and Provides Corporate Update PR Newswire SAN MATEO, Calif., Nov...\n more…

AcelRx to Host KOL Panel Discussion on Current Anticoagulant Use in Dialysis and the Upcoming Niyad Clinical Study
AcelRx to Host KOL Panel Discussion on Current Anticoagulant Use in Dialysis and the Upcoming Niyad Clinical Study

PR Newswire AcelRx to Host KOL Panel Discussion on Current Anticoagulant Use in Dialysis and the Upcoming Niyad Clinical Study AcelRx to Host KOL Panel Discussion on Current Anticoagulant Use in Dialysis and the...\n more…

AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Short Interest Up 22.9% in October
AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Short Interest Up 22.9% in October

Zolmax AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX Get Free Report) was the target of a large increase in short interest during the month of October. As of October 15th, there was short interest...\n more…

AcelRx to Host Third Quarter 2023 Financial Results Call and Webcast on November 8, 2023
AcelRx to Host Third Quarter 2023 Financial Results Call and Webcast on November 8, 2023

PR Newswire AcelRx to Host Third Quarter 2023 Financial Results Call and Webcast on November 8, 2023 AcelRx to Host Third Quarter 2023 Financial Results Call and Webcast on November 8, 2023 PR Newswire HAYWARD...\n more…

Values First Advisors Inc. Raises Stock Position in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX)
Values First Advisors Inc. Raises Stock Position in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX)

Ticker Report Values First Advisors Inc. raised its position in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX Free Report) by 201.7% in the second quarter, according to its most recent Form 13F filing with the...\n more…